Turtle Cameron sold $1.3M of SYRE
Turtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.69 ($87.44–$88.91, $1.32M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The key new information is the disclosed sale size, trade dates, and the fact it was executed under a 10b5-1 plan, which can influence short-term sentiment but not fundamentals directly.
Market read
Traders may monitor for follow-on insider activity or changes in ownership, but the 10b5-1 label reduces the likelihood of an immediate fundamental repricing.
What to watch
The filing does not disclose reasons for the sale or whether other insiders/large holders acted; traders should avoid over-weighting a single pre-planned transaction.
Background
The article is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, Inc. (SYRE).
Ticker impact
Spyre Therapeutics CEO Turtle Cameron sold $1.32M of SYRE stock via open-market trades under a 10b5-1 plan on 2026-07-01.
Likely limited near-term price impact; any effect is more about sentiment than fundamentals.
Form 4 shows a sizable sale (15,000 shares; ~$1.32M) but explicitly notes a pre-arranged 10b5-1 plan, which typically dampens the market’s inference of new negative information.
Market effects
No sector-level implications; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.
Key entities
- issuerSpyre Therapeutics, Inc.
US-listed biotech issuer whose CEO executed open-market sales disclosed on Form 4.
- insiderTurtle Cameron
CEO and director who sold 15,000 SYRE shares for ~$1.32M across three trades.
